Skip to main content

C-RAD advances approval of interim report for Q3 2025

C-RAD,a global leader in SGRT,announces today that, in light of the management changes resolved, the board has decided to bring forward the board meeting to approve the company's interim report for the third quarter of 2025. The distribution of the interim report for Q3 2025 is planned to take place tonight, October 21, 2025, after an extraordinary board meeting.

The board of directors has its regular meeting tomorrow, October 22, 2025. The company's executive management consisting of acting CEO and CFO Linda Frölén and deputy CEO Johan Danielsson will hold the investor presentation as planned on October 23 at 11 a.m.

For more information, please contact acting CEO Linda Frölén

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit https://www.c-rad.com

Attachments

C-RAD advances approval of interim report for Q3 2025

C-RAD advances approval of interim report for Q3 2025
Close Menu